Latest Competition News

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

betr Entertainment has lodged a formal application with the Takeovers Panel, contesting PointsBet’s board decision to accelerate vesting of performance rights amid competing takeover bids, a move that significantly boosted MIXI’s voting power.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

EPX Limited reported a 17.2% increase in revenue to $15.27 million for FY2025, alongside an 18.7% rise in net loss to $5.75 million. The company expanded its energy management portfolio with the acquisition of UK-based Coda Cloud Limited and raised $5 million in equity to fuel growth.

Hubify Limited reports a significant turnaround in FY25 with positive EBITDA and a robust cash position, despite a strategic revenue decline. The company’s focus on recurring managed services and cybersecurity positions it well for future growth.

Thrive Tribe Technologies has raised approximately $250,000 through a discounted share placement, aiming to bolster its working capital. The move reflects ongoing efforts to support its health and wellness digital platform.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

PointsBet reports a 6% revenue increase and returns to normalised EBITDA profitability in FY25, while the board unanimously backs MIXI Australia’s all-cash $1.25 per share takeover offer, urging shareholders to reject a rival hostile bid.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Harvey Norman Holdings Limited has announced a fully franked ordinary dividend of AUD 0.145 per share for the six months ending June 2025, signaling steady returns for shareholders.

Harvey Norman Holdings Limited reported robust FY25 results with strong sales growth, a significant profit increase, and a major boost from property revaluations. The company’s integrated retail, franchise, and property model continues to underpin its expansion and resilience.